Related Experiment Video
Updated: Jan 15, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin-Based Therapy and Referred or Not to a Weight
Kathleen M Robinson1,2, Stephanie H Rodriguez3, Cyril Pedagarla4
1The University of Iowa Hospitals and Clinics Department of Internal Medicine Iowa City Iowa USA.
Background:
Incretin therapies yield strong metabolic improvements, but whether adding a weight-management (WM) clinic confers additional benefit beyond pharmacotherapy alone in routine care is unclear.
Objective:
Evaluate whether referral to WM clinic, alongside standard diabetes care, provides additional benefit for adults with type 2 diabetes (T2DM) and obesity treated with incretin therapies regarding changes in A1c, body weight, and LDL.
Methods:
Retrospective cohort study within an academic health system (2018-2023); adults with T2DM and obesity initiating an incretin were grouped by care model (diabetes care alone, DM, vs. diabetes care plus WM clinic, DM + WM). N = 1445 (DM n = 1,163, DM + WM n = 282). The DM + WM group was stratified based on the number of visits. Primary outcomes were change from baseline to last follow-up in A1c (%), body weight (kg), and LDL (mg/dL). Weighted linear models reported within-group changes and between-group adjusted mean differences with 95% CIs, controlling for baseline values and prespecified covariates (sex, race/ethnicity, age, comorbidity, medication categories, care period).
Results:
Among 1445 patients (DM n = 1163; DM + WM n = 282), both groups improved from baseline: weight -4.95 versus -6.00 kg, A1c -0.38% versus -0.37%, LDL -12.19 versus -11.60 mg/dL (all within-group p < 0.05). In adjusted models, the DM + WM (1 visit) group lost less weight than the DM group by +4.1 kg (95% CI 1.2-7.1 kg; p = 0.006) while the DM + WM (4 + visit) group lost more weight with of -4.4 kg (95% CI -6.7 to -2.0 kg, p = 0.0003). Other differences were not statistically significant: A1c + 0.01% (-0.27 to 0.28; p = 0.96), LDL + 0.58 mg/dL (-6.01 to 7.16; p = 0.86).
Conclusion:
Among adults starting incretin therapy in routine practice, significant improvements in A1c, weight, and LDL were observed. Patients attending one weight management visit lost less weight than those attending only the DM clinic, while those attending 4 + WM visits lost significantly more weight. Potential long-term effects of WM-based support were not assessed.
More Related Videos
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
08:06Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
Published on: November 27, 2019
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Type 2 and Gestational
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Dipeptidyl Peptidase 4 Inhibitors